王雪强

王雪强


  • 电子邮件:wangxueqiang@him.cas.cn

个人简历

2012年硕士毕业于中国科学院上海有机化学研究所,2015年博士毕业于西班牙加泰罗尼亚化学研究所,2016-2017年在美国麻省理工学院从事博士后研究。2017年在湖南大学化学化工学院开始研究工作,2023年加入中国科学院杭州医学研究所。以通讯作者身份在Sing. Transduct. Target. Ther.; J. Am. Chem. Soc.; Angew. Chem. Int. Ed. 等国内外高水平期刊发表学术论文30余篇,申请中国专利28余项,已授权14项。入选国家青年人才计划,2019 湖湘青年英才计划,2021 湖南省芙蓉学者奖励计划-特聘教授,2022 湖南省杰出青年基金,获2022 Thieme Chemistry Journals Award。

研究方向

1.核酸适体偶联药物 利用核酸适体的特异性靶向能力和小分子抗肿瘤药物的强大杀伤能力,致力于核酸适体偶联药物(ApDC)的基础与转化研究,实现癌症靶向药物的自主创新。 2.自主靶向核药 利用特异性识别能力突出的靶向配体和放射性核素的强大杀伤能力,结合临床致力于自主靶向核药的集成创新与转化应用。 3.协同靶向配体 开发识别配体的修饰及偶联新方法,实现协同靶向配体的精准构建,应用于医学检测新技术的开发。 4.新型化学发光探针 设计具有全新骨架结构的化学发光探针,应用于医学检测新技术的开发

承担科研项目情况

1.中国科学院杭州医学研究所自主选题项目,自主靶向核药开发与临床应用研究,项目负责人,900万元,2024-2027 2.浙江省尖兵领雁计划,基于人工智能和细胞特异性递送技术开发个性化 mRNA 肿瘤疫苗,项目负责人,900万元,2024-2026 3.国家重点研发计划“ 生命科学仪器中的关键配套试剂耗材研发”项目,课题负责人,534万元,2023-2028 4.湖南省杰出青年基金项目,项目负责人,50万元,2022-2024 5.国家重点研发计划“高通量脱氧核糖核酸(DNA)合成新技术及仪器研发”项目,参与,2019-2024 6.湖南创新型省份建设专项-湖湘青年英才,项目负责人,50万元,2019-2022 7.湖南省重点研发计划“抗肿瘤药物生物合成及恶性肿瘤靶向治疗研究”,课题负责人,80万元,2019-2022

代表论著

1) DNA-Compatible Photoredox Atom Transfer Radical Addition to Alkynes with Thiosulfonates Cong Wang, Yinghui Lu, Zhiyuan Peng, Chi Zhang, Qingchao Liu*, Xue-Qiang Wang*, Tiezheng Jia* CCS Chemistry, 2024, online 2) Aptamer Glue-Catalysis Enables Hyperefficient Targeted Membrane Protein Degradation Guo-Rong Zhang, Chi Zhang, Ting Fu, Weihong Tan, and Xue-Qiang Wang* JACS Au, 2024, 4, 2907–2914. 3) Chemical Tailoring of Aptamer Glues with Significantly Enhanced Recognition Ability for Targeted Membrane Protein Degradation Zhang, Guo-Rong; Tan, Weihong; Wang, Xue-Qiang* ACS Nano, 2023, 17, 15146-15154. 4) Regulating the Properties of XQ-2d for Targeted Therapeutic Agents Delivery to Pancreatic Cancer Qiuxia Yang, Yongbo Peng, Zhengyu Deng, Dailiang Zhang, Cheng-Yu Long, Guo-Rong Zhang, Juan Li, Xue-Qiang Wang*, Weihong Tan* National Science Review, 2023, 10, nwad113. 5) A Versatile Strategy for Convenient Circular Bivalent Functional Nucleic Acids Construction Xiao-Jing Zhang, Zhuo Zhao, Xia Wang, Min-Hui Su, Yingying Li, Quan Yuan, Xue-Qiang Wang*, Weihong Tan National Science Review, 2023, 10, nwac107. 6) Dual‐targeting Circular Aptamer Strategy Enabled Recognition of Different Leukemia Cells with Enhanced Binding Ability Lili Ai, Tianhuan Peng, Yingying Li, Hailan Kuai, Yingyu Sima, Minhui Su, Dan Wang, Qiuxia Yang, Xue-Qiang Wang*, Weihong Tan Angew. Chem. Int. Ed. 2022, 61, e202109500. 7) A new paradigm for artesunate anticancer function: considerably enhancing the cytotoxicity via conjugating artesunate with aptamer Yingying Li, Y. Peng, Yan Tan, Wenjing Xuan, Ting Fu, Xue-Qiang Wang*, Weihong Tan* Sig. Transduct. Target. Ther. 2021, 6, 327. 8) Regulating the Anticancer Efficacy of Sgc8–Combretastatin A4 Conjugates: A Case of Recognizing the Significance of Linker Chemistry for the Design of Aptamer-Based Targeted Cancer Therapy Zhiyong Huang, Dan Wang, Cheng-Yu Long, Shen-Huan Li, Xue-Qiang Wang*, Weihong Tan* J. Am. Chem. Soc. 2021, 143, 8559–8564. 9) Molecularly Engineered Aptamers Targeting Tumor Tissue and Cancer Cells for Efficient in vivo Recognition and Enrichment Xia Wang, Xiao-Jing Zhang, Yingying Li, Guo-Rong Zhang, Juan Li, Xue-Qiang Wang*, Weihong Tan CCS Chemistry, 2022, 4, 2581–2587. 10) Hierarchical Fabrication of DNA Wireframe Nanoarchitectures for Efficient Cancer Imaging and Targeted Therapy Dan Wang, Ruizi Peng, Yongbo Peng, Zhengyu Deng, Fengyuan Xu, Yuanye Su, Pengfei Wang, Ling Li, Xue-Qiang Wang*, Yonggang Ke*, Weihong Tan* ACS Nano, 2020, 14, 17365-17375. 11)Highly Chemoselective Access to 2,2'-Diaminobiaryls via Ni-Catalyzed Protecting-Group-Free Coupling of 2-Haloanilines Cheng-Yu Long#, Shaofei Ni#, Min-Hui Su#, Xue-Qiang Wang*, Weihong Tan ACS Catalysis, 2020, 10, 13641–13649. 12)Conjugating Aptamer and Mitomycin C with Reductant-Responsive Linker Leading to Synergistically Enhanced Anticancer Effect Qiuxia Yang, Zhengyu Deng, Dan Wang, Jiaxuan He, Dailiang Zhang, Yan Tan, Tianhuan Peng, Xue-Qiang Wang*, Weihong Tan* J. Am. Chem. Soc. 2020, 142, 2532-2540. 13)Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer Jiaxuan He, Tianhuan Peng, Yongbo Peng, Lili Ai, Zhengyu Deng, Xue-Qiang Wang*, Weihong Tan* J. Am. Chem. Soc. 2020, 142, 2532-2540. 14)Functional nucleic acids for cancer theranostics Tianhuan Peng, Zhengyu Deng, Jiaxuan He, Yingying Li, Yan Tan, Yongbo Peng, Xue-Qiang Wang*, Weihong Tan* Coordination Chemistry Reviews, 2020, 213080.

获奖及荣誉

1)入选国家青年人才计划 2)2022 Thieme Chemistry Journals Award 3)2022 湖南省杰出青年基金获得者 4)2021 湖南省芙蓉学者奖励计划-特聘教授 5)2019 湖湘青年英才计划 6)申请发明专利28项,已授权14项